Otonomy, Inc. (NASDAQ:OTIC) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On November 30, 2016, Otonomy, Inc. (the “Company”) is presenting at the 28th Annual Piper Jaffray Healthcare Conferencein New York City. At the presentation, the Company is informing the attendees that the Company has fully enrolled its Phase 3 clinical trial of OTIPRIO® in patients with acute otitis externa (AOE), with 262 patients enrolled, and that it expects to announce topline results from this trial as soon as available, which the Company expects to be within four to six weeks.
All of the information furnished in this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.
About Otonomy, Inc. (NASDAQ:OTIC)
Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company has developed a technology referred to as sustained-exposure that is designed to deliver drug that is retained in the ear for an extended period of time following a local administration. Its product candidates include OTIPRIO, OTO-104 and OTO-311. The Company’s product candidate, OTIPRIO, is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery. Its product candidate, OTO-104, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere’s disease and other inner ear conditions. The Company’s product candidate, OTO-311, is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. Otonomy, Inc. (NASDAQ:OTIC) Recent Trading Information
Otonomy, Inc. (NASDAQ:OTIC) closed its last trading session 00.00 at 17.75 with 68,558 shares trading hands.